Hat die jemand

ich hätte ihm ja 0.11 oder sogar 0,115 für die paar Teile gegeben. Hätte nur was sagen müssen.  

Making A Comeback


http://www.insiderfinancial.com/...semktheb-making-a-comeback/114732/  

Making these moves will go a long way in establishing management’s credibility and keep the stock heading higher. Overall, we do see potential with HEB and believe that with Dr. Carter gone, a turnaround is not only possible, but highly likely

..."nicht nur möglich, sondern sehr wahrscheinlich "  

Hemispherx Biopharma Reviews Ampligen(R) Data With National Institute of Neurological Disorders and Stroke (NINDS)

http://www.marketwatch.com/story/...rders-and-stroke-ninds-2016-03-10  

sich gut heute im Markt !!



 

 

30k vom CEO

http://www.sec.gov/Archives/edgar/data/946644/...5X03/primary_doc.xml  

https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=HEB  

http://www.biospace.com/News/...=sm&type=twitter_Hemispherx031115  

40k vom CEO

http://www.sec.gov/Archives/edgar/data/946644/...5X03/primary_doc.xml  

Form 8-K for HEMISPHERX BIOPHARMA INC


16-Mar-2016

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St



Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or   Standard; Transfer of Listing.  
On March 15, 2016, Hemispherx Biopharma, Inc. (the "Company") received written notice from the NYC MKT LLC (the "NYSE MKT") that it is not in compliance with the continued listing standards set forth in Section 1003(f)(v) of the NYSE MKT Company Guide because the Company's common stock has been selling for a low price per share for a substantial period of time. The NYSE MKT has determined that the continued listing of the Company's common stock is predicated on the Company effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time. The Company has until September 15, 2016 to demonstrate compliance.

The Company plans to seek stockholder approval of a reverse stock split at the Annual Stockholders' Meeting which it anticipates holding in late August 2016. In the interim, as discussed below, the Company will continue to actively pursue its new honed business focus in the hopes that such actions will increase stockholder value and raise the price of its common stock. The Company cannot assure that its actions will demonstrate compliance.

The Company has been reexamining its fundamental priorities in terms of direction, corporate culture and its ability to fund operations. As a result, there have been significant changes at the Company in the past few months. The CEO of the Company was terminated and the Board of Directors have made several changes to the Company's executive management team to provide effective and competent leadership that, management believes, will properly position the Company to achieve its commercial goals and increase stockholder value. Recent actions include listing for sale underutilized assets, aggressively pursuing international sales of clinical grade materials, and implementing a strong financial austerity plan. The Company is committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of its experimental drug and its approved drug Alferon�. Management's primary objectives are to create stockholder value and deliver much needed therapies to patients. In this regard, since the implementation of these actions, the stock price of the Company's common stock has increased from approximately $0.10 prior to the implementation of these actions, to a high of $0.19 and, as of the March 15, 2016, the closing price on the NYSE MKT was $0.16.

There is no immediate impact on the listing of the Company's common stock, which will continue to trade on the NYSE MKT, subject to the Company's compliance with other listing standards.

Forward-Looking Statements:  

This report on Form 8-K contains forward-looking statements that can be identified by words such as "will be, believes, anticipates, interim, potential" or similar terms. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the actions that the Company has taken or will take will prove successful or cure the NYSE MKT deficiency. Management's expectations regarding Ampligen� could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K on file with the U.S. Securities and Exchange Commission. Hemispherx is providing the information in this report as of this date and does not undertake any obligation to update any forward-looking statements contained in this report as a result of new information, future events or otherwise.

Information contained in this report, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties including, but not limited to, general industry conditions and competition; general economic factors; the Company's ability to adequately fund its projects; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; trends toward healthcare cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company's ability to accurately predict the future market conditions; manufacturing difficulties or delays; dependence on the effectiveness of the Company's patents and other protections for products; and the exposure to litigation, including patent litigation, and/or regulatory actions; as well as numerous other factors discussed in this report and in the Company's filings with the Securities and Exchange Commission. The final results of these efforts could vary materially from Hemispherx's expectations.




 

erst mal keine so tolle News, haben Zeit bis 15.09.16 de  Share-Price zu erhöhen..

das Managment hat ja diesbezüglich ein Programm gestarte vom $0,20 mindesten einer
Woche, könnte schnell erreicht werden, wenn es das ist !


die Frage ist für mich gerade, wohin der Preis muss ($0,20 ??)..in den Amex Rules steht nix von $1


v) Low Selling Price Issues—In the case of a common stock selling for a substantial period of time at a low price per share, if the issuer shall fail to effect a reverse split of such shares within a reasonable time after being notified that the Exchange deems such action to be appropriate under all the circumstances. In its review of the question of whether it deems a reverse split of a given issue to be appropriate, the Exchange will consider all pertinent factors including, market conditions in general, the number of shares outstanding, plans which may have been formulated by management, applicable regulations of the state or country of incorporation or of any governmental agency having jurisdiction over the issuer, the relationship to other Exchange policies regarding continued listing, and, in respect of securities of foreign issuers, the general practice in the country of origin of trading in low-selling price issues.

http://wallstreet.cch.com/mkt/companyguide/...ide/chp_1_1/default.asp


und es stehen noch bis August 2 Katalysatoren an !!

mal schauen  

erfahren wir ja morgen mehr mit Veröffentlichung des Quartalsberichts  

nochmal der CEO mit 30k

http://www.sec.gov/Archives/edgar/data/946644/...5X03/primary_doc.xml  

ist raus....



Cash and cash equivalents $2,115M by issued and outstanding 247,559,487 Shares


http://www.sec.gov/Archives/edgar/data/946644/...4671/s102655_10k.htm  

On March 3, 2016, Hemispherx Biopharma, Inc. (the “Company”) entered into a Sales, Marketing, Distribution and Supply Agreement (the “Agreement”) with Scientific Products Pharmaceutical Co. LTD, a Saudi Arabia based pharmaceutical company (“Scien”). Pursuant to the Agreement, the Company granted Scien an exclusive license to sell, market and distribute human leukocyte derived Interferon alfa-n3 (the “Product”) for refractory/recurrent genital warts, recombinant interferon refractory patients and patients with other infectious diseases, e.g., Middle East Respiratory Syndrome (“MERS”), influenza, West Nile Virus and cancer (the “Field”) within the Gulf Cooperation Council states (the “Territory”) for Direct Access/EAP and Regulatory Agency-Approved purposes.


http://www.edgarexplorer.com/EFX_dll/...4iexsQiLpcIT9&ID=11296838  

haben Sie auch ihre Website ein neues Gesicht verpasst dazu der neue Partner


denke hier hat die Metamorphose begonnen :-)  

Wollen wir das mal hoffen.  

HEB auch mal wieder etwas los im Pre


http://www.nasdaq.com/de/symbol/heb/premarket  

Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease

http://finance.yahoo.com/news/...pharma-enters-alfa-n3-123000329.html  

0.129
-0.003 (-2.05%)
After Hours: 0.151 +0.022 (17.24%)
Apr 5, 4:11PM EDT  
NYSEMKT real-time data - Disclaimer  

schardtechnisch interessant, es steht ein golden cross an

was eigentlicht für Vol. sorgt ;-)

der RSi ist angenehm, und der MACD steht auch kurz vor bullish cross


mal schauen

 

bei den a.bulls


https://www.americanbulls.com/SignalPage.aspx?lang=de&Ticker=HEB  

eine ganz interessante Woche hier :-)

MACD hat den bullish cross vollzogen, die BBs haben sich schön zusammengezogen

alles wartet auf den golden cross !!


 

Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon(R) and Ampligen(R)

http://www.marketwatch.com/story/...alferonr-and-ampligenr-2016-04-20